Adverum Biotechnologies, Inc.

Quick facts

Phase 2 pipeline

• ADVM-022 · Ophthalmology
  ADVM-022 is an adeno-associated virus (AAV) vector-based gene therapy that targets the vascular endothelial growth factor A (VEGF-A) gene.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Adverum Biotechnologies, Inc. portfolio CI brief
• Adverum Biotechnologies, Inc. pipeline updates RSS